Menu

Infographic: Tumor-Associated Macrophages and Cancer

The immune cells play various roles in the tumor—some that assist cancer's spread, and others that hinder it.

Mar 31, 2018
Amanda B. Keener

T

umors use chemokine signals to draw monocytes and tissue-resident macrophages into the tumor microenvironment, where the cells become tumor-associated macrophages (TAMs). Once believed to be wholly supportive of cancerous growth, these cells also play important roles in protecting against disease.

Tumor-assisting macrophages: The M2 phenotype

TAMs can take on a variety of roles to support cancer cell survival and dissemination. Originating either from monocytes that come from bone marrow, or tissue-resident macrophages that arise during embryonic development, they can repress antitumor immunity by secreting cytokines such as IL-10, which blocks dendritic cell activation, and TGF-β, which blunts T-cell responses (1). A specific subset of TAMs that produce a protein called Tie2 can also stimulate angiogenesis through secretion of vascular endothelial growth factor (VEGF) and other molecules (2). At the same time, Tie2+ macrophages come together with cancer cells and blood vessel endothelial cells to form complexes, called tumor microenvironments of metastasis (TMEMs), that create openings in blood vessels (3). Macrophages at distant sites then help cancer cells exit blood vessels and seed new tumors (4).

© SCOTT LEIGHTON

 

Tumor-killing macrophages: The M1 phenotype

TAMs have the potential to aid antitumor immune responses by presenting cancer cell antigens to T cells and producing cytokines that activate dendritic cells and T cells (1). Macrophages are also experts at phagocytosing and degrading foreign cells, including cancer cells (2).

 
 
© SCOTT LEIGHTON

Read the full story.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.